Fundraising Fox

Prelude Therapeutics

NASDAQ: PRLD

Newark, US · Founded 2016 · Delaware corporation · 2 known investors

preludetx.com ↗

Prelude Therapeutics develops precision oncology medicines, including selective KAT6A degraders, mutant-selective JAK2 inhibitors, and degrader antibody conjugates for cancer treatment. The company focuses on clinically validated targets with high unmet medical needs in oncology.

AI & Machine LearningBiotechMedical Devicesin /prelude-therapeutics@PreludeTx

Founders & leadership

KV
Krishna VaddiExecutive Officer, Director
PF
Paul FriedmanDirector of Issuer
DB
David BonitaDirector of Issuer

Investors · 2

OrbiMedNew York · $1M – $75Mvia David Bonita · board
The Innovation SpaceWilmington · $200K

Reported raises · per SEC filings

Form D private placements
▶$50MraisedAug 2020 · 7 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • David BonitaDirector
  • Victor SandorDirector
  • Peggy ScherleExecutive Officer
  • Christopher PierceExecutive Officer
  • Deborah MorosiniExecutive Officer
  • Krishna VaddiExecutive Officer, Director
  • Brian PiperExecutive Officer
  • Mardi C. DierDirector
  • Paul FriedmanDirector
  • Kelvin NeuDirector
  • David MauroExecutive Officer
  • Andrew CombsExecutive Officer
Offering amount
$50M
Amount sold
$50M
First sale
Aug 2020
Incorporated
Corporation, Delaware, 2016
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$30MraisedJun 2019 · 6 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Krishna VaddiExecutive Officer, Director
  • David MauroExecutive Officer
  • Peggy ScherleExecutive Officer
  • Kelvin NeuDirector
  • David BonitaDirector
  • Paul FriedmanDirector
Offering amount
$60M
Amount sold
$30M
First sale
May 2019
Incorporated
Corporation, Delaware, 2016
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$30MraisedAug 2018 · 7 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Juan LuengoExecutive Officer
  • David BonitaDirector
  • Paul FriedmanDirector
  • Kelvin NeuDirector
  • Krishna VaddiExecutive Officer, Director
Offering amount
$30M
Amount sold
$30M
First sale
Oct 2017
Incorporated
Corporation, Delaware, 2016
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$5MraisedJul 2016 · 8 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Krishna VaddiExecutive Officer, Director
  • Paul FriedmanDirector
  • David BonitaDirector
Offering amount
$5M
Amount sold
$5M
First sale
Jun 2016
Incorporated
Corporation, Delaware, 2016
Federal exemptions
06b
Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

In the news